Pink Sheet

Alimera Resubmits Iluvien In U.S. As It Begins EU Launch

26 Mar 2013

• By Lisa LaMotta

The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.

With an Iluvien approval still far from reality in the U.S., Alimera Sciences Inc. turns its attention to launching the ophthalmologic product in Europe.